Embracing body positivity while using Ozempic - a drug I utilized for pain management, not weight reduction. Let's discuss the reasons behind this choice.
A prominent figure in the cycling community, known for promoting weight-neutral cycling spaces and championing size inclusion, has been navigating the impact of a recent health decision on their body and public image. The individual, who leads the nonprofit organization All Bodies on Bikes, has been open about their struggle with chronic pain and their journey towards managing their health.
In an unexpected turn, the individual was diagnosed with insulin resistant PCOS and started taking GLP-1 receptor agonists, a class of medications originally developed to treat Type 2 diabetes but increasingly prescribed for weight management. These drugs, known for their significant appetite-suppressing effect, have helped the individual manage their weight and reduce their food intake.
However, the individual has noticed some side effects, including mild nausea and constipation, and has been mindful of the message these medications might send to their community. They have emphasized that their decision to take the medication was a personal one, made in consultation with their healthcare provider, and not a reflection of any pressure to conform to societal beauty standards.
The changes in the individual's body and riding have been noticeable. Clothes feel looser, and they have seen their collarbone for the first time. They have also experienced a decrease in chronic joint pain and inflammation. Their cycling performance has improved, with consistent personal records on familiar segments.
However, the use of GLP-1 receptor agonists presents challenges for endurance athletes. These drugs can lead to unintended caloric deficits, muscle loss, reduced metabolic rate, gastrointestinal issues, and impaired hydration, all of which can negatively impact athletic performance if not carefully managed under medical supervision [1][2][3][4].
Experts stress the importance of tailoring nutrition and hydration strategies for athletes on GLP-1 agonists, including accurate metabolic rate measurement and ensuring sufficient protein intake to help mitigate muscle loss [1][2][3].
From a regulatory perspective, the use of GLP-1 agonists in elite sports is a topic of ongoing discussion at the World Anti-Doping Agency (WADA), due to their variable performance effects and weight-loss benefits [1].
Despite the changes in their body and the attention they have received, the individual remains committed to promoting size inclusion and encouraging plus-size riders. Their story serves as a reminder that health is not one-size-fits-all and that everyone deserves access to tools that help them feel good in their bodies, no matter what they look like.
[1] [Expert Source 1] [2] [Expert Source 2] [3] [Expert Source 3] [4] [Expert Source 4]
- The individual, a prominent figure in the cycling community, has been taking GLP-1 receptor agonists, a class of medications often used for weight management and diabetes treatment, to manage their health conditions, specifically insulin-resistant PCOS.
- While these medications have helped the individual manage their weight and reduce food intake, they have also experienced side effects such as mild nausea and constipation, and the individual is mindful of the message these medications might send to their community.
- The individual's decision to take the medication was a personal one, made in consultation with their healthcare provider, and not a reflection of any pressure to conform to societal beauty standards.
- In addition to approaches for managing side effects, experts stress the importance of tailoring nutrition and hydration strategies for athletes on GLP-1 agonists, considering factors like accurate metabolic rate measurement and sufficient protein intake to help mitigate muscle loss.
